The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial
Abstract Background According to the World Health Organization, cardiovascular diseases (CVDs) are the leading non-communicable cause of death. Awareness of the individual risk profile is crucial to implement a healthy lifestyle and prevent CVDs. Multiple studies demonstrated that atherosclerosis, t...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-02-01
|
Series: | BMC Cardiovascular Disorders |
Online Access: | https://doi.org/10.1186/s12872-020-01357-9 |
id |
doaj-f2941af2825f4e67a3e2d8e50fd42173 |
---|---|
record_format |
Article |
spelling |
doaj-f2941af2825f4e67a3e2d8e50fd421732021-02-07T12:26:03ZengBMCBMC Cardiovascular Disorders1471-22612020-02-0120111010.1186/s12872-020-01357-9The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trialBenoît Bernar0Nina Gande1Katharina A. Stock2Anna Staudt3Raimund Pechlaner4Ralf Geiger5Andrea Griesmacher6Stefan Kiechl7Michael Knoflach8Ursula Kiechl-Kohlendorfer9for the Early Vascular Aging (EVA) Study GroupDepartment of Neurology, Medical University of InnsbruckDepartment of Pediatrics II, Medical University of InnsbruckDepartment of Pediatrics II, Medical University of InnsbruckDepartment of Pediatrics II, Medical University of InnsbruckDepartment of Neurology, Medical University of InnsbruckDepartment of Pediatrics III, Medical University of InnsbruckCentral Institute of Clinical Chemistry and Laboratory Medicine (ZIMCL), Medical University of InnsbruckDepartment of Neurology, Medical University of InnsbruckDepartment of Neurology, Medical University of InnsbruckDepartment of Pediatrics II, Medical University of InnsbruckAbstract Background According to the World Health Organization, cardiovascular diseases (CVDs) are the leading non-communicable cause of death. Awareness of the individual risk profile is crucial to implement a healthy lifestyle and prevent CVDs. Multiple studies demonstrated that atherosclerosis, the main cause of CVDs, begins early in life. Therefore, it may be necessary to start prevention programs already in childhood. Methods The EVA-Tyrol study is a population-based non-randomized controlled trial that will prospectively enroll 2000 participants from high schools and training companies in North- and East-Tyrol (Austria) and South-Tyrol (Italy). Participants will be assigned to either an intervention (n = 1500) or a control (n = 500) group. Intervention group participants will be enrolled at the 10th school grade (mean age 15–16 years), undergo two examinations within a two-year interval, with follow-up at the 12th grade (mean ages 17–18 years). Control group participants will be enrolled at the 12th grade (mean age 17–18 years). Medical examination will include anthropometric measurements, comprehensive lifestyle and dietary questionnaires, a fasting blood sample, high-resolution ultrasound of the carotid arteries, and measurement of carotid-femoral pulse wave velocity. Active intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) an online health promotion tool and (4) involvement of participants in planning and implementation of health promotion projects. Effectiveness of the intervention will be assessed by comparing the proportion subjects with ideal health metrics as defined by the American Heart Association between study groups. Discussion This study aims to improve cardiovascular health in Tyrolean adolescents by demonstrating the efficacy of a multi-layer health promotion program and may yield novel insights into the prevalence of vascular risk conditions and mechanisms of early vascular pathologies in adolescents. Trial registration EVA-Tyrol has been retrospectively registered at clinicaltrials.gov under NCT03929692 since April 29, 2019.https://doi.org/10.1186/s12872-020-01357-9 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Benoît Bernar Nina Gande Katharina A. Stock Anna Staudt Raimund Pechlaner Ralf Geiger Andrea Griesmacher Stefan Kiechl Michael Knoflach Ursula Kiechl-Kohlendorfer for the Early Vascular Aging (EVA) Study Group |
spellingShingle |
Benoît Bernar Nina Gande Katharina A. Stock Anna Staudt Raimund Pechlaner Ralf Geiger Andrea Griesmacher Stefan Kiechl Michael Knoflach Ursula Kiechl-Kohlendorfer for the Early Vascular Aging (EVA) Study Group The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial BMC Cardiovascular Disorders |
author_facet |
Benoît Bernar Nina Gande Katharina A. Stock Anna Staudt Raimund Pechlaner Ralf Geiger Andrea Griesmacher Stefan Kiechl Michael Knoflach Ursula Kiechl-Kohlendorfer for the Early Vascular Aging (EVA) Study Group |
author_sort |
Benoît Bernar |
title |
The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial |
title_short |
The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial |
title_full |
The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial |
title_fullStr |
The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial |
title_full_unstemmed |
The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial |
title_sort |
tyrolean early vascular ageing-study (eva-tyrol): study protocol for a non-randomized controlled trial |
publisher |
BMC |
series |
BMC Cardiovascular Disorders |
issn |
1471-2261 |
publishDate |
2020-02-01 |
description |
Abstract Background According to the World Health Organization, cardiovascular diseases (CVDs) are the leading non-communicable cause of death. Awareness of the individual risk profile is crucial to implement a healthy lifestyle and prevent CVDs. Multiple studies demonstrated that atherosclerosis, the main cause of CVDs, begins early in life. Therefore, it may be necessary to start prevention programs already in childhood. Methods The EVA-Tyrol study is a population-based non-randomized controlled trial that will prospectively enroll 2000 participants from high schools and training companies in North- and East-Tyrol (Austria) and South-Tyrol (Italy). Participants will be assigned to either an intervention (n = 1500) or a control (n = 500) group. Intervention group participants will be enrolled at the 10th school grade (mean age 15–16 years), undergo two examinations within a two-year interval, with follow-up at the 12th grade (mean ages 17–18 years). Control group participants will be enrolled at the 12th grade (mean age 17–18 years). Medical examination will include anthropometric measurements, comprehensive lifestyle and dietary questionnaires, a fasting blood sample, high-resolution ultrasound of the carotid arteries, and measurement of carotid-femoral pulse wave velocity. Active intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) an online health promotion tool and (4) involvement of participants in planning and implementation of health promotion projects. Effectiveness of the intervention will be assessed by comparing the proportion subjects with ideal health metrics as defined by the American Heart Association between study groups. Discussion This study aims to improve cardiovascular health in Tyrolean adolescents by demonstrating the efficacy of a multi-layer health promotion program and may yield novel insights into the prevalence of vascular risk conditions and mechanisms of early vascular pathologies in adolescents. Trial registration EVA-Tyrol has been retrospectively registered at clinicaltrials.gov under NCT03929692 since April 29, 2019. |
url |
https://doi.org/10.1186/s12872-020-01357-9 |
work_keys_str_mv |
AT benoitbernar thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT ninagande thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT katharinaastock thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT annastaudt thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT raimundpechlaner thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT ralfgeiger thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT andreagriesmacher thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT stefankiechl thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT michaelknoflach thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT ursulakiechlkohlendorfer thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT fortheearlyvascularagingevastudygroup thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT benoitbernar tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT ninagande tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT katharinaastock tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT annastaudt tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT raimundpechlaner tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT ralfgeiger tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT andreagriesmacher tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT stefankiechl tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT michaelknoflach tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT ursulakiechlkohlendorfer tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial AT fortheearlyvascularagingevastudygroup tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial |
_version_ |
1724281169841750016 |